procainamide

Procainamide (Novocainamide) is a specific and potent DNA methyltransferase 1 (DNMT1) inhibitor and a Class 1A antiarrhythmic agent, with potential applications in cancer and arrhythmia research [1] [2].

Procainamide Hydrochloride (Procapan) is the hydrochloride salt form of procainamide, an amide derivative exhibiting class 1A antiarrhythmic property and analog of procaine. Procainamide hydrochloride reversibly binds to and blocks activated (open) voltage-gated sodium channels, thereby blocks the influx of sodium ions into the cell, which leads to an increase in threshold for excitation and inhibit depolarization during phase 0 of the action potential.

Procainamide-d10 is a deuterated compound of Procainamide. Procainamide has a CAS number of 51-06-9. Procainamide is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1). Procainamide is a Class 1A antiarrhythmic agent. Procainamide has the potential for the research of cancer and arrhythmias.

N-Acetylprocainamide (NAPA), the N-acetylated metabolite of Procainamide, is a Class III antiarrhythmic agent, while procainamide is a Class Ia antiarrhythmic drug.

DA 1686 is a therapeutic antiarrhythmic compound.DA 1686 reduces the tachycardic effects of aconitine. It also reduces the effects of increased frequency of electrical stimulation and is 1.8 times more active than quinidine and 9 times more active than procainamide.

CH 200 is a novel antiarrhythmic drug that inhibits arrhythmias in beagles more effectively than procainamide and lidocaine.

Acecainide hydrochloride (NAPA) is the major hepatic metabolite of procainamide and its antiarrhythmic effects may lead to cardiotoxicity in renal failure.